Agius, M. A., Klodowska-Duda, G., Maciejowski, M., Potemkowski, A., Li, J., Patra, K., . . . Flor, A. (2017). Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler.
Chicago Style aipamenaAgius, Mark A., et al. "Safety and Tolerability of Inebilizumab (MEDI-551), an Anti-CD19 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis: Results From a Phase 1 Randomised, Placebo-controlled, Escalating Intravenous and Subcutaneous Dose Study." Mult Scler 2017.
MLA aipamenaAgius, Mark A., et al. "Safety and Tolerability of Inebilizumab (MEDI-551), an Anti-CD19 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis: Results From a Phase 1 Randomised, Placebo-controlled, Escalating Intravenous and Subcutaneous Dose Study." Mult Scler 2017.